Different vaccine formulations for RSV or H5 flu in adults 18–49

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 1, interventional trial enrolling healthy adults aged 18 to 49 to receive one of several investigational vaccine formulations encoding either an RSV monovalent antigen or the influenza H5 hemagglutinin antigen. Participants are assigned to arms across two stages and followed for approximately 6–7 months depending on their arm to monitor safety and immune responses. The study collects safety data and measures immunogenicity, primarily antibody responses, after vaccination. Multiple investigational product formulations are compared to identify tolerable formulations that elicit biologically meaningful immune signals.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged 18 to 49 years on the day of inclusion
* A female participant is eligible to participate if she is not pregnant or breastfeeding and of the following conditions applies:
* Is of NCBP (Non-Child-Bearing Potential). To be considered of NCBP, a female must be post-menopausal for at least 1 year, or surgically sterile. OR
* Is of CBP (Child-Bearing Potential) and uses an effective contraceptive method or abstinence from at least 4 weeks prior to study intervention administration until at least 12 weeks after the last study intervention administration.

Exclusion Criteria:

• Any condition which, in the opinion of the Investigator, might interfere with the evaluation of the study objectives

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Where it's running

• Site # 0361002
  Griffith, Queensland, Australia Recruiting
• Site # 0361001
  Herston, Queensland, Australia Recruiting
• Site # 0361003
  Morayfield, Queensland, Australia Recruiting
• Site # 0361005
  Sippy Downs, Queensland, Australia Recruiting
• Site # 03610004
  South Brisbane, Queensland, Australia Recruiting
• Site # 036006
  Taringa, Queensland, Australia Recruiting

Study contacts

• Study coordinator: Sanofi Trial Transparency Email Recommended (Toll free for US and Canada)
• Email: contact-us@sanofi.com
• Phone: 800-633-1610

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• RSV vaccine safety and immune response in lung transplant patients vs. healthy adults

  This study tests how well the RSV vaccine works and how safe it is in people who have had a lung transplant compared with healthy adults.

  Recruiting Phase 4 Seoul National University Hospital · Seoul, Jongno-Gu · NCT07895394

• RSV vaccine in children at high risk to see if it is safe and makes a strong immune response

  This study tests whether the RSVpreF vaccine is safe and helps the immune system in children aged 5 to under 18 who are at high risk for RSV illness, including those who are immunocompromised.

  Recruiting at 11 sites Phase 3 Pfizer · Durham, North Carolina and 19 other locations · NCT07839871

• Revaccination with RSVpreF in Immunocompromised Adults

  This study tests whether giving an RSVpreF vaccine shot again at about 1, 2, and 3 years is safe and can still provoke an immune response in adults who are immunocompromised.

  Recruiting at 13 sites Phase 3 Pfizer · Los Angeles, California and 16 other locations · NCT07768345

• Vaccine candidates for RSV and hMPV in older adults

  This study tests whether mRNA-1365 and related vaccine profiles are safe and able to trigger an immune response in healthy older adults.

  Recruiting at 2 sites Phase 1 ModernaTX, Inc. · Québec, Quebec and 9 other locations · NCT07764237

• YKYY025 Injection safety and immune response test in adults

  This phase 1 study tests whether YKYY025 is safe and prompts an immune response in healthy adults.

  Recruiting Phase 1 Youcare Pharmaceutical Group Co., Ltd. · Anning, Yunnan · NCT07694557

• RSVpreF vaccine in adults: safety and immune response in India

  A Phase 3 test of the RSVpreF vaccine vs placebo in adults 18 and older living in India to see if it is safe and produces an immune response.

  Recruiting at 13 sites Phase 3 Pfizer · Visakhapatnam, Andhra Pradesh and 12 other locations · NCT07653100

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.